FDA Adverse Event Injury Summary report: N

WATCHMAN FLX LEFT ATRIAL APPENDAGE CLOSURE DEVICE WITH DELIVERY SYSTEM

MDR report key: 11554834 · Received March 23, 2021

Report

Report Number
2134265-2021-03615
Event Type
Injury
Date Received
March 23, 2021
Date of Event
October 30, 2020
Report Date
March 23, 2021
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
NGV
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CO, US
Reporter Occupation
PHYSICIAN

Narratives

Description of Event or Problem · 1

(B)(6) STUDY. IT WAS REPORTED THAT A TRANSIENT ISCHEMIC ATTACK (TIA) OCCURRED. PRIOR TO THE INDEX PROCEDURE APIXABAN WAS ADMINISTERED. A LEFT ATRIAL APPENDAGE (LAA) CLOSURE PROCEDURE WAS PERFORMED AND A 27MM WATCHMAN FLX LAA CLOSURE DEVICE WAS IMPLANTED WITH A COMPLETE LAA SEAL AND DEPLOYED DEVICE DIAMETER OF 23.5 MM. AFTER THE IMPLANT THE SUBJECT WAS STARTED ON BOTH ASPIRIN AND APIXABAN. ON (B)(6) 2020, THE SUBJECT WAS DISCHARGED. A 3-MONTH FOLLOW-UP TEE WAS PERFORMED ON (B)(6) 2020 AND THE RESULTS DID NOT REVEAL ANY EVIDENCE OF THROMBUS. ON (B)(6) 2020, THE SUBJECT WAS ADMITTED TO THE HOSPITAL FOR REPEAT ABLATION OF ATYPICAL ATRIAL FLUTTER. THE SUBJECT UNDERWENT SUCCESSFUL ABLATION OF ATYPICAL FLUTTER AND PULMONARY VEIN ISOLATION ABLATION FOR ATRIAL FIBRILLATION (AF). DUE TO SUBJECT'S HIGH RISK OF FALLS, HISTORY OF CHRONIC ANTICOAGULATION, STROKE DUE TO EMBOLISM OF RIGHT POSTERIOR CEREBRAL ARTERY, THE SUBJECT WAS RECOMMENDED FOR AN MAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN OF THE HEAD AND NECK. ON (B)(6) 2020, 106 DAYS POST INDEX PROCEDURE, THE SUBJECT WAS DIAGNOSED WITH TIA FOLLOWING THE REPEAT AF ABLATION. AT THE TIME OF EVENT, THE SUBJECT WAS ON ASPIRIN AND APIXABAN. NO CORRECTIVE ACTION WAS PERFORMED TO TREAT THE EVENT AND ON (B)(6) 2020, THE EVENT WAS CONSIDERED RESOLVED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
451932 WATCHMAN FLX LEFT ATRIAL APPENDAGE CLOSURE DEVICE WITH DELIVERY SYSTEM SYSTEM, APPENDAGE CLOSURE, LEFT ATRIAL NGV BOSTON SCIENTIFIC CORPORATION 10393 0024354602

Patients

Seq Age Sex Outcome Treatment
1 80 YR Other